Crescimento e metabolismo de mudas de Pityrocarpa moniliformis Benth. sob deficit hídrico

Pityrocarpa moniliformis Benth. has medicinal properties, forage potential, besides showing rusticity and rapid growth, which confer potential to recover degraded areas. In this context, the objective was to evaluate the growth and biochemical components of Pityrocarpa moniliformis seedlings under water deficit conditions. The design used was randomized blocks, with five treatments and four replicates, with the experimental plot consisting of twenty plants. Treatments were characterized by different periods of water deficit (0; 4; 8; 12 and 16 days without irrigation). At 44 days after sowing (DAS), when the seedlings had two pairs of fully formed true leaves, the treatments began to be applied. The development of the seedlings was evaluated until 60 DAS when they were collected for biometric and biochemical analyses. The variables analyzed were shoot height; collar diameter; number of leaves; shoot dry mass; root dry mass; root/shoot ratio; and Dickson’s quality index. Contents of total chlorophyll, chlorophyll a, chlorophyll b, total free amino acids, total soluble sugar, and proline contents in the leaves were also determined. The treatment most affected by the lack of irrigation was 16 days of water deficit, which resulted in the death of 38.8% of the seedlings. This condition caused a decrease in shoot length, reducing it by approximately 29.2% compared to the control treatment. There was also a reduction in the production of new leaves from the eighth day after the differentiation of treatments. Pityrocarpa moniliformis seedlings can develop under the condition of water deficit for up to 8 days, even with chlorophyll degradation due to stress. Pityrocarpa moniliformis maintains its vegetative development by performing osmotic adjustment through the accumulation of biomolecules (sugars, proline, and amino acids).Pityrocarpa moniliformis Benth. possui propriedades medicinais, potencial forrageiro, além de apresentar rusticidade e rápido crescimento, o que lhe confere potencialidade de uso para recuperação de áreas degradadas. Nesse contexto, objetivou-se avaliar o crescimento e os componentes bioquímicos de mudas de Pityrocarpa moniliformis em condições de deficit hídrico. O delineamento foi em blocos casualizados, com cinco tratamentos e quatro repetições, sendo a parcela experimental composta por vinte plantas. Os tratamentos foram caracterizados por diferentes períodos de deficit hídrico (0; 4; 8; 12 e 16 dias sem irrigação). Aos 44 dias após a semeadura (DAS), quando as mudas apresentaram dois pares de folhas verdadeiras totalmente formadas, iniciou-se a aplicação dos tratamentos. O desenvolvimento das mudas foi avaliado até os 60 DAS, período em que ocorreu a coleta destas para as análises biométricas e bioquímicas. As variáveis analisadas foram: altura da parte aérea; diâmetro do colo; número de folhas; massa seca de parte aérea e raiz; relação entre raiz e parte aérea; e índice de qualidade de Dickson. Também foram determinados nas folhas os teores de clorofilas totais, a e b; aminoácidos livres totais; teor de açúcares solúveis totais; e teor de prolina. O tratamento mais afetado pela falta de irrigação foi o de 16 dias, o qual acarretou a morte de 38,8% das mudas. Essa condição ocasionou a diminuição no comprimento da parte aérea das mudas, com redução de aproximadamente 29,2%, quando comparado ao tratamento-controle. Houve também redução da emissão de novas folhas a partir do oitavo dia após a diferenciação dos tratamentos. Mudas de Pityrocarpa moniliformis conseguem se desenvolver em condição de deficit hídrico por até 8 dias, mesmo ocorrendo a degradação de clorofilas devido ao estresse. A manutenção do desenvolvimento vegetativo de Pityrocarpa moniliformis ocorre devido à realização de ajustamento osmótico pelo acúmulo de biomoléculas (açúcares, prolina e aminoácidos)

PRE-GERMINATION TREATMENT OF CARROT SEEDS WITH BIOACTIVATOR

Carrot is a vegetable with an important socio-economic role, both due to the employment of labor and high commercialization. To optimize the establishment of this crop in fields, seeds with rapid and uniform germination are essential. Therefore, various seed treatment techniques have been used to enable and enhance the germination percentage and optimize the vigor of the seeds. In continuation with this, the objective of this study was to evaluate the effects of thiamethoxam on the physiological performance of carrot seeds during germination and initial development of seedlings. The experimental design was a completely randomized design in a 5 × 4 factorial scheme, with five carrot cultivars and four doses of thiamethoxam (0, 0.4, 0.8, and 1.2 mL). Parameters such as germination, first germination count, seedling length, and dry mass were evaluated. In addition, biochemical analyses of total sugars, total amino acids, and proline content were performed. In general, the treatment of carrot seeds with thiamethoxam positively influenced the germination of the seeds of the cultivars studied. However, thiamethoxam doses of 0.4 and 0.8 mL had no positive effect on the seedling development of the Tropical cultivar. The thiamethoxam dose of 1.2 mL was beneficial to the development of seedlings and accumulation of metabolites in the Alvorada cultivar.A cenoura é uma hortaliça com papel socioeconômico importante, tanto pelo elevado emprego de mão-de-obra, quanto por sua alta comercialização. Para otimizar o estabelecimento dessa cultura em campo se torna imprescindível sementes com germinação rápida e uniforme. Por isso, tem-se utilizado o tratamento de sementes como técnica para viabilizar o desempenho germinativo e expressão de vigor. Desse modo, objetivou-se avaliar os efeitos do tiametoxam no desempenho fisiológico de sementes de cenoura durante a germinação e desenvolvimento inicial de plântulas. O delineamento experimental foi o inteiramente casualizado, em esquema fatorial 5 x 4, sendo cinco cultivares de cenoura e quatro dosagens de tiametoxam (0; 0,4; 0,8 e 1,2 mL). Avaliaram-se a germinação, primeira contagem de germinação, comprimento e massa seca de plântula, além de análises bioquímicas do conteúdo de açúcares totais, aminoácidos totais e prolina. Os dados coletados foram submetidos à análise de variância (p ≤ 0,05) seguido do teste de Tukey e análise de regressão. O tratamento de sementes de cenoura com tiametoxam, no geral, influenciou positivamente a germinação das sementes das cultivares estudadas. No entanto, as dosagens de 0,4 e 0,8 mL de tiametoxam para cultivar Tropical não houve influência positivamente o desenvolvimento de plântulas. A dose de 1,2 mL do bioativador, para a cultivar Alvorada, foi benéfico ao desenvolvimento de plântulas e acúmulo de metabólitos

Pre-germination treatments with plant growth regulators and bioactivators attenuate salt stress in melon: effects on germination and seedling development

The scarcity of surface water has led to the use of underground sources as an alternative for crop irrigation by farmers in semi-arid regions. However, these water sources generally have high salinity, which prevents agricultural production. The objective of this study was to determine the effects of pre-germination treatments with plant growth regulators and bioactivators on melon seeds to attenuate salt stress caused by irrigation water during germination and seedling development. Two trials were carried out separately with the hybrids, Goldex and Grand Prix. The design was completely randomized in a 4 × 3 factorial scheme (four seed treatments and three dilutions of irrigation water). Seeds were treated with salicylic acid and gibberellic acid and the insecticide, thiamethoxam, in addition to the control. Local supply water, artesian well groundwater, and dilution of these waters at a 1:1 ratio were employed for irrigation. Fourteen days after sowing, morphological and physiological analyses were performed, and the material was collected for biochemical determination. The use of saline well water affected the initial development of melon seedlings of the Goldex and Grand Prix hybrids. Pre-germination treatment of Goldex hybrid seeds with gibberellic acid was inefficient at mitigating salt stress. However, the effects of irrigation water salinity on Grand Prix melon seeds pretreated with salicylic acid and thiamethoxam were attenuated

Erratum to: The study of cardiovascular risk in adolescents – ERICA: rationale, design and sample characteristics of a national survey examining cardiovascular risk factor profile in Brazilian adolescents

1585

Catálogo Taxonômico da Fauna do Brasil: setting the baseline knowledge on the animal diversity in Brazil

The limited temporal completeness and taxonomic accuracy of species lists, made available in a traditional manner in scientific publications, has always represented a problem. These lists are invariably limited to a few taxonomic groups and do not represent up-to-date knowledge of all species and classifications. In this context, the Brazilian megadiverse fauna is no exception, and the Catálogo Taxonômico da Fauna do Brasil (CTFB) (http://fauna.jbrj.gov.br/), made public in 2015, represents a database on biodiversity anchored on a list of valid and expertly recognized scientific names of animals in Brazil. The CTFB is updated in near real time by a team of more than 800 specialists. By January 1, 2024, the CTFB compiled 133,691 nominal species, with 125,138 that were considered valid. Most of the valid species were arthropods (82.3%, with more than 102,000 species) and chordates (7.69%, with over 11,000 species). These taxa were followed by a cluster composed of Mollusca (3,567 species), Platyhelminthes (2,292 species), Annelida (1,833 species), and Nematoda (1,447 species). All remaining groups had less than 1,000 species reported in Brazil, with Cnidaria (831 species), Porifera (628 species), Rotifera (606 species), and Bryozoa (520 species) representing those with more than 500 species. Analysis of the CTFB database can facilitate and direct efforts towards the discovery of new species in Brazil, but it is also fundamental in providing the best available list of valid nominal species to users, including those in science, health, conservation efforts, and any initiative involving animals. The importance of the CTFB is evidenced by the elevated number of citations in the scientific literature in diverse areas of biology, law, anthropology, education, forensic science, and veterinary science, among others

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

How long one lives, how many years of life are spent in good and poor health, and how the population's state of health and leading causes of disability change over time all have implications for policy, planning, and provision of services. We comparatively assessed the patterns and trends of healthy life expectancy (HALE), which quantifies the number of years of life expected to be lived in good health, and the complementary measure of disability-adjusted life-years (DALYs), a composite measure of disease burden capturing both premature mortality and prevalence and severity of ill health, for 359 diseases and injuries for 195 countries and territories over the past 28 years. Methods We used data for age-specific mortality rates, years of life lost (YLLs) due to premature mortality, and years lived with disability (YLDs) from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to calculate HALE and DALYs from 1990 to 2017. We calculated HALE using age-specific mortality rates and YLDs per capita for each location, age, sex, and year. We calculated DALYs for 359 causes as the sum of YLLs and YLDs. We assessed how observed HALE and DALYs differed by country and sex from expected trends based on Socio-demographic Index (SDI). We also analysed HALE by decomposing years of life gained into years spent in good health and in poor health, between 1990 and 2017, and extra years lived by females compared with males. Findings Globally, from 1990 to 2017, life expectancy at birth increased by 7·4 years (95% uncertainty interval 7·1-7·8), from 65·6 years (65·3-65·8) in 1990 to 73·0 years (72·7-73·3) in 2017. The increase in years of life varied from 5·1 years (5·0-5·3) in high SDI countries to 12·0 years (11·3-12·8) in low SDI countries. Of the additional years of life expected at birth, 26·3% (20·1-33·1) were expected to be spent in poor health in high SDI countries compared with 11·7% (8·8-15·1) in low-middle SDI countries. HALE at birth increased by 6·3 years (5·9-6·7), from 57·0 years (54·6-59·1) in 1990 to 63·3 years (60·5-65·7) in 2017. The increase varied from 3·8 years (3·4-4·1) in high SDI countries to 10·5 years (9·8-11·2) in low SDI countries. Even larger variations in HALE than these were observed between countries, ranging from 1·0 year (0·4-1·7) in Saint Vincent and the Grenadines (62·4 years [59·9-64·7] in 1990 to 63·5 years [60·9-65·8] in 2017) to 23·7 years (21·9-25·6) in Eritrea (30·7 years [28·9-32·2] in 1990 to 54·4 years [51·5-57·1] in 2017). In most countries, the increase in HALE was smaller than the increase in overall life expectancy, indicating more years lived in poor health. In 180 of 195 countries and territories, females were expected to live longer than males in 2017, with extra years lived varying from 1·4 years (0·6-2·3) in Algeria to 11·9 years (10·9-12·9) in Ukraine. Of the extra years gained, the proportion spent in poor health varied largely across countries, with less than 20% of additional years spent in poor health in Bosnia and Herzegovina, Burundi, and Slovakia, whereas in Bahrain all the extra years were spent in poor health. In 2017, the highest estimate of HALE at birth was in Singapore for both females (75·8 years [72·4-78·7]) and males (72·6 years [69·8-75·0]) and the lowest estimates were in Central African Republic (47·0 years [43·7-50·2] for females and 42·8 years [40·1-45·6] for males). Globally, in 2017, the five leading causes of DALYs were neonatal disorders, ischaemic heart disease, stroke, lower respiratory infections, and chronic obstructive pulmonary disease. Between 1990 and 2017, age-standardised DALY rates decreased by 41·3% (38·8-43·5) for communicable diseases and by 49·8% (47·9-51·6) for neonatal disorders. For non-communicable diseases, global DALYs increased by 40·1% (36·8-43·0), although age-standardised DALY rates decreased by 18·1% (16·0-20·2)

Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: A systematic analysis from the Global Burden of Disease Study 2016

Copyright © 2018 The Author(s). Published by Elsevier Ltd. Background A key component of achieving universal health coverage is ensuring that all populations have access to quality health care. Examining where gains have occurred or progress has faltered across and within countries is crucial to guiding decisions and strategies for future improvement. We used the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) to assess personal health-care access and quality with the Healthcare Access and Quality (HAQ) Index for 195 countries and territories, as well as subnational locations in seven countries, from 1990 to 2016. Methods Drawing from established methods and updated estimates from GBD 2016, we used 32 causes from which death should not occur in the presence of effective care to approximate personal health-care access and quality by location and over time. To better isolate potential effects of personal health-care access and quality from underlying risk factor patterns, we risk-standardised cause-specific deaths due to non-cancers by location-year, replacing the local joint exposure of environmental and behavioural risks with the global level of exposure. Supported by the expansion of cancer registry data in GBD 2016, we used mortality-to-incidence ratios for cancers instead of risk-standardised death rates to provide a stronger signal of the effects of personal health care and access on cancer survival. We transformed each cause to a scale of 0-100, with 0 as the first percentile (worst) observed between 1990 and 2016, and 100 as the 99th percentile (best); we set these thresholds at the country level, and then applied them to subnational locations. We applied a principal components analysis to construct the HAQ Index using all scaled cause values, providing an overall score of 0-100 of personal health-care access and quality by location over time. We then compared HAQ Index levels and trends by quintiles on the Socio-demographic Index (SDI), a summary measure of overall development. As derived from the broader GBD study and other data sources, we examined relationships between national HAQ Index scores and potential correlates of performance, such as total health spending per capita. Findings In 2016, HAQ Index performance spanned from a high of 97·1 (95% UI 95·8-98·1) in Iceland, followed by 96·6 (94·9-97·9) in Norway and 96·1 (94·5-97·3) in the Netherlands, to values as low as 18·6 (13·1-24·4) in the Central African Republic, 19·0 (14·3-23·7) in Somalia, and 23·4 (20·2-26·8) in Guinea-Bissau. The pace of progress achieved between 1990 and 2016 varied, with markedly faster improvements occurring between 2000 and 2016 for many countries in sub-Saharan Africa and southeast Asia, whereas several countries in Latin America and elsewhere saw progress stagnate after experiencing considerable advances in the HAQ Index between 1990 and 2000. Striking subnational disparities emerged in personal health-care access and quality, with China and India having particularly large gaps between locations with the highest and lowest scores in 2016. In China, performance ranged from 91·5 (89·1-93·6) in Beijing to 48·0 (43·4-53·2) in Tibet (a 43·5-point difference), while India saw a 30·8-point disparity, from 64·8 (59·6-68·8) in Goa to 34·0 (30·3-38·1) in Assam. Japan recorded the smallest range in subnational HAQ performance in 2016 (a 4·8-point difference), whereas differences between subnational locations with the highest and lowest HAQ Index values were more than two times as high for the USA and three times as high for England. State-level gaps in the HAQ Index in Mexico somewhat narrowed from 1990 to 2016 (from a 20·9-point to 17·0-point difference), whereas in Brazil, disparities slightly increased across states during this time (a 17·2-point to 20·4-point difference). Performance on the HAQ Index showed strong linkages to overall development, with high and high-middle SDI countries generally having higher scores and faster gains for non-communicable diseases. Nonetheless, countries across the development spectrum saw substantial gains in some key health service areas from 2000 to 2016, most notably vaccine-preventable diseases. Overall, national performance on the HAQ Index was positively associated with higher levels of total health spending per capita, as well as health systems inputs, but these relationships were quite heterogeneous, particularly among low-to-middle SDI countries. Interpretation GBD 2016 provides a more detailed understanding of past success and current challenges in improving personal health-care access and quality worldwide. Despite substantial gains since 2000, many low-SDI and middle- SDI countries face considerable challenges unless heightened policy action and investments focus on advancing access to and quality of health care across key health services, especially non-communicable diseases. Stagnating or minimal improvements experienced by several low-middle to high-middle SDI countries could reflect the complexities of re-orienting both primary and secondary health-care services beyond the more limited foci of the Millennium Development Goals. Alongside initiatives to strengthen public health programmes, the pursuit of universal health coverage hinges upon improving both access and quality worldwide, and thus requires adopting a more comprehensive view - and subsequent provision - of quality health care for all populations

Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017

Background: Efforts to establish the 2015 baseline and monitor early implementation of the UN Sustainable Development Goals (SDGs) highlight both great potential for and threats to improving health by 2030. To fully deliver on the SDG aim of “leaving no one behind”, it is increasingly important to examine the health-related SDGs beyond national-level estimates. As part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), we measured progress on 41 of 52 health-related SDG indicators and estimated the health-related SDG index for 195 countries and territories for the period 1990–2017, projected indicators to 2030, and analysed global attainment. Methods: We measured progress on 41 health-related SDG indicators from 1990 to 2017, an increase of four indicators since GBD 2016 (new indicators were health worker density, sexual violence by non-intimate partners, population census status, and prevalence of physical and sexual violence [reported separately]). We also improved the measurement of several previously reported indicators. We constructed national-level estimates and, for a subset of health-related SDGs, examined indicator-level differences by sex and Socio-demographic Index (SDI) quintile. We also did subnational assessments of performance for selected countries. To construct the health-related SDG index, we transformed the value for each indicator on a scale of 0–100, with 0 as the 2\ub75th percentile and 100 as the 97\ub75th percentile of 1000 draws calculated from 1990 to 2030, and took the geometric mean of the scaled indicators by target. To generate projections through 2030, we used a forecasting framework that drew estimates from the broader GBD study and used weighted averages of indicator-specific and country-specific annualised rates of change from 1990 to 2017 to inform future estimates. We assessed attainment of indicators with defined targets in two ways: first, using mean values projected for 2030, and then using the probability of attainment in 2030 calculated from 1000 draws. We also did a global attainment analysis of the feasibility of attaining SDG targets on the basis of past trends. Using 2015 global averages of indicators with defined SDG targets, we calculated the global annualised rates of change required from 2015 to 2030 to meet these targets, and then identified in what percentiles the required global annualised rates of change fell in the distribution of country-level rates of change from 1990 to 2015. We took the mean of these global percentile values across indicators and applied the past rate of change at this mean global percentile to all health-related SDG indicators, irrespective of target definition, to estimate the equivalent 2030 global average value and percentage change from 2015 to 2030 for each indicator. Findings: The global median health-related SDG index in 2017 was 59\ub74 (IQR 35\ub74–67\ub73), ranging from a low of 11\ub76 (95% uncertainty interval 9\ub76–14\ub70) to a high of 84\ub79 (83\ub71–86\ub77). SDG index values in countries assessed at the subnational level varied substantially, particularly in China and India, although scores in Japan and the UK were more homogeneous. Indicators also varied by SDI quintile and sex, with males having worse outcomes than females for non-communicable disease (NCD) mortality, alcohol use, and smoking, among others. Most countries were projected to have a higher health-related SDG index in 2030 than in 2017, while country-level probabilities of attainment by 2030 varied widely by indicator. Under-5 mortality, neonatal mortality, maternal mortality ratio, and malaria indicators had the most countries with at least 95% probability of target attainment. Other indicators, including NCD mortality and suicide mortality, had no countries projected to meet corresponding SDG targets on the basis of projected mean values for 2030 but showed some probability of attainment by 2030. For some indicators, including child malnutrition, several infectious diseases, and most violence measures, the annualised rates of change required to meet SDG targets far exceeded the pace of progress achieved by any country in the recent past. We found that applying the mean global annualised rate of change to indicators without defined targets would equate to about 19% and 22% reductions in global smoking and alcohol consumption, respectively; a 47% decline in adolescent birth rates; and a more than 85% increase in health worker density per 1000 population by 2030. Interpretation: The GBD study offers a unique, robust platform for monitoring the health-related SDGs across demographic and geographic dimensions. Our findings underscore the importance of increased collection and analysis of disaggregated data and highlight where more deliberate design or targeting of interventions could accelerate progress in attaining the SDGs. Current projections show that many health-related SDG indicators, NCDs, NCD-related risks, and violence-related indicators will require a concerted shift away from what might have driven past gains—curative interventions in the case of NCDs—towards multisectoral, prevention-oriented policy action and investments to achieve SDG aims. Notably, several targets, if they are to be met by 2030, demand a pace of progress that no country has achieved in the recent past. The future is fundamentally uncertain, and no model can fully predict what breakthroughs or events might alter the course of the SDGs. What is clear is that our actions—or inaction—today will ultimately dictate how close the world, collectively, can get to leaving no one behind by 2030

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

The Global Burden of Diseases, Injuries and Risk Factors 2017 includes a comprehensive assessment of incidence, prevalence, and years lived with disability (YLDs) for 354 causes in 195 countries and territories from 1990 to 2017. Previous GBD studies have shown how the decline of mortality rates from 1990 to 2016 has led to an increase in life expectancy, an ageing global population, and an expansion of the non-fatal burden of disease and injury. These studies have also shown how a substantial portion of the world's population experiences non-fatal health loss with considerable heterogeneity among different causes, locations, ages, and sexes. Ongoing objectives of the GBD study include increasing the level of estimation detail, improving analytical strategies, and increasing the amount of high-quality data. METHODS: We estimated incidence and prevalence for 354 diseases and injuries and 3484 sequelae. We used an updated and extensive body of literature studies, survey data, surveillance data, inpatient admission records, outpatient visit records, and health insurance claims, and additionally used results from cause of death models to inform estimates using a total of 68 781 data sources. Newly available clinical data from India, Iran, Japan, Jordan, Nepal, China, Brazil, Norway, and Italy were incorporated, as well as updated claims data from the USA and new claims data from Taiwan (province of China) and Singapore. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between rates of incidence, prevalence, remission, and cause of death for each condition. YLDs were estimated as the product of a prevalence estimate and a disability weight for health states of each mutually exclusive sequela, adjusted for comorbidity. We updated the Socio-demographic Index (SDI), a summary development indicator of income per capita, years of schooling, and total fertility rate. Additionally, we calculated differences between male and female YLDs to identify divergent trends across sexes. GBD 2017 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting